X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Reldesemtiv (CK-2127107), is an investigational, selective, small molecule fast skeletal muscle troponin activator (FSTA) arising from Cytokinetics’ skeletal muscle contractility program.
Lead Product(s): Reldesemtiv
Therapeutic Area: Neurology Product Name: CK-2127107
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2022
Details:
Reldesemtiv is an investigational, selective, small molecule fast skeletal muscle troponin activator (FSTA) arising from Cytokinetics’ skeletal muscle contractility program.
Lead Product(s): Reldesemtiv
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 10, 2022
Details:
CK-2127107 (Reldesemtiv) investigational, selective, small molecule fast skeletal muscle troponin activator arising from Cytokinetics’ skeletal muscle contractility, was designed to slow rate of calcium release from regulatory troponin complex of fast skeletal muscle fibers.
Lead Product(s): Reldesemtiv
Therapeutic Area: Neurology Product Name: CK-2127107
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 16, 2022
Details:
The primary objective of the collaboration was to advance novel therapies for diseases and medical conditions associated with muscle weakness. In addition, Astellas had an exclusive license to co-develop Cytokinetics' drug candidate CK-2127107 in certain indications.
Lead Product(s): Reldesemtiv
Therapeutic Area: Neurology Product Name: CK-2127107
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Astellas Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Termination May 03, 2021
Details:
Cytokinetics is developing reldesemtiv, as a potential treatment for people with ALS, SMA and certain other debilitating diseases and conditions associated with skeletal muscle weakness or fatigue.
Lead Product(s): Reldesemtiv
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 04, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
